HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kensei Tobinai Selected Research

Rituximab (Mabthera)

3/2021A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
2/2021Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study.
2/2021The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.
1/2021Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
1/2021Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A.
1/2021A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.
3/2020Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.
1/2020A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.
10/2019Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
11/2018Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kensei Tobinai Research Topics

Disease

59Lymphoma (Lymphomas)
10/2022 - 01/2002
53Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2022 - 12/2002
46Neoplasms (Cancer)
09/2022 - 01/2002
27B-Cell Lymphoma (Lymphoma, B Cell)
01/2022 - 01/2002
21Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
02/2021 - 05/2004
20Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2021 - 08/2003
19Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
10/2022 - 03/2010
19Multiple Myeloma
12/2021 - 10/2007
18Infections
11/2019 - 03/2002
17Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
06/2021 - 12/2002
16Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
08/2022 - 02/2003
15Neutropenia
02/2021 - 02/2002
13Hodgkin Disease (Hodgkin's Disease)
04/2021 - 02/2003
12Disease Progression
12/2020 - 02/2003
11Thrombocytopenia (Thrombopenia)
02/2021 - 12/2007
10Lymphopenia (Lymphocytopenia)
06/2021 - 08/2010
10T-Cell Lymphoma (Lymphoma, T Cell)
01/2020 - 12/2002
8Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
10/2022 - 05/2011
8Pneumonia (Pneumonitis)
12/2021 - 02/2003
8B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
03/2021 - 01/2009
8Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2018 - 06/2003
7Hematologic Neoplasms (Hematological Malignancy)
11/2016 - 04/2002
6Graft vs Host Disease (Graft-Versus-Host Disease)
10/2017 - 03/2002
6Anemia
01/2016 - 10/2006
5Fever (Fevers)
06/2021 - 11/2008
5Leukopenia
12/2016 - 08/2010
4Myelodysplastic Syndromes (Myelodysplastic Syndrome)
04/2017 - 08/2007
4Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2016 - 09/2007
3Diarrhea
12/2020 - 10/2004
3Hepatitis
10/2019 - 12/2014
3Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
07/2019 - 07/2004
3Exanthema (Rash)
03/2018 - 01/2016
3Fatigue
03/2018 - 10/2006
3Sepsis (Septicemia)
01/2018 - 02/2003
3Nausea
11/2016 - 08/2010
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2011 - 07/2007
3Anorexia
04/2011 - 01/2010
3Leukemia
09/2010 - 04/2002
2Hypoalbuminemia
06/2021 - 03/2018

Drug/Important Bio-Agent (IBA)

53Rituximab (Mabthera)FDA Link
03/2021 - 01/2002
23Vincristine (Oncovin)FDA LinkGeneric
10/2022 - 02/2003
22Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 02/2003
22Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022 - 08/2003
22Monoclonal AntibodiesIBA
10/2020 - 01/2002
14Prednisolone (Predate)FDA LinkGeneric
01/2021 - 02/2003
12mogamulizumabIBA
08/2022 - 03/2010
11Bortezomib (Velcade)FDA Link
12/2021 - 06/2007
10Prednisone (Sone)FDA LinkGeneric
10/2022 - 06/2005
9Dexamethasone (Maxidex)FDA LinkGeneric
06/2021 - 04/2011
9Bendamustine HydrochlorideFDA Link
10/2018 - 09/2010
8Brentuximab VedotinIBA
04/2021 - 07/2014
8Pharmaceutical PreparationsIBA
02/2021 - 02/2007
7CladribineFDA LinkGeneric
07/2009 - 04/2002
6obinutuzumabIBA
10/2019 - 01/2013
6CCR4 ReceptorsIBA
05/2019 - 03/2012
6Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2018 - 02/2002
5Etoposide (VP 16)FDA LinkGeneric
12/2020 - 02/2003
5Lenalidomide (CC 5013)FDA Link
11/2020 - 03/2016
5Immunoconjugates (Immunoconjugate)IBA
09/2020 - 09/2002
5AntibodiesIBA
09/2020 - 08/2003
5VorinostatFDA Link
01/2018 - 01/2010
4Histone Deacetylase InhibitorsIBA
09/2022 - 01/2010
4Biomarkers (Surrogate Marker)IBA
12/2021 - 05/2008
4Transaminases (Aminotransferases)IBA
06/2021 - 11/2010
4ibrutinibIBA
06/2021 - 01/2016
4Adenosine Monophosphate (AMP)IBA
12/2020 - 12/2007
410-propargyl-10-deazaaminopterinFDA Link
01/2020 - 04/2010
4DNA (Deoxyribonucleic Acid)IBA
10/2019 - 05/2004
4carfilzomibIBA
09/2019 - 03/2016
4forodesineIBA
01/2019 - 07/2012
4Proteins (Proteins, Gene)FDA Link
02/2018 - 02/2005
4Inotuzumab OzogamicinIBA
01/2018 - 08/2010
4CalicheamicinsIBA
10/2016 - 05/2009
3pomalidomideIBA
06/2021 - 01/2015
3fludarabineIBA
03/2021 - 07/2004
3NivolumabIBA
10/2020 - 03/2017
3Agammaglobulinaemia Tyrosine KinaseIBA
09/2020 - 01/2016
3GalliumIBA
10/2019 - 10/2018
3Anti-Bacterial Agents (Antibiotics)IBA
07/2019 - 08/2010
3Alanine Transaminase (SGPT)IBA
03/2018 - 10/2004
3Anaplastic Lymphoma KinaseIBA
02/2018 - 07/2012
3Biological ProductsIBA
11/2017 - 03/2014
3Melphalan (Alkeran)FDA LinkGeneric
01/2016 - 04/2011
3Proteasome InhibitorsIBA
01/2008 - 06/2007
3ibritumomab tiuxetan (Zevalin)FDA Link
01/2007 - 10/2002
2Histone Deacetylases (Histone Deacetylase)IBA
09/2022 - 10/2012
2Cyclin D1IBA
06/2021 - 01/2002
2pembrolizumabIBA
06/2021 - 11/2020
2Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
02/2021 - 02/2015

Therapy/Procedure

57Therapeutics
10/2022 - 03/2002
49Drug Therapy (Chemotherapy)
08/2022 - 12/2002
14Stem Cell Transplantation
10/2020 - 04/2002
13Hematopoietic Stem Cell Transplantation
04/2022 - 07/2006
8Radioimmunotherapy
01/2009 - 10/2002
7Transplantation
01/2018 - 07/2002
5Radiotherapy
02/2021 - 06/2005
5Chemoradiotherapy
01/2018 - 02/2006
5Combination Drug Therapy (Combination Chemotherapy)
04/2016 - 02/2003
3Cell Transplantation
01/2018 - 08/2007
3Homologous Transplantation
01/2018 - 04/2002